HIMS vs NVO Stock Comparison: AI Score, Valuation, Performance and Upside
Hims & Hers is typically evaluated as a fast-growing consumer health platform whose fortunes are increasingly tied to its distribution relationship with GLP-1 manufacturers, while Novo Nordisk is judged as the underlying drug innovator and manufacturer defending its franchise against rivals and new distribution channels. The two now sit on opposite ends of the same supply chain after settling their 2026 legal dispute and striking a partnership. The choice between them depends on whether an investor wants exposure to branded drug economics or to the consumer-facing distribution layer.
Novo Nordisk suits investors seeking established, profitable exposure to GLP-1 drug economics at a pharma valuation, while Hims & Hers is a higher-beta bet on telehealth distribution scaling faster than its subscriber-acquisition costs.
NVO holds the edge across 4 of 5 key metrics in this comparison. NVO leads on both 1-year return (-27.40%) and forward P/E quality (1.71x vs 29.03x for HIMS), a relatively favorable combination of momentum and valuation. On fundamentals, HIMS is growing revenue faster (38.20%), while NVO maintains the higher operating margin (42.54%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for NVO (+17.00%) than for HIMS (+7.36%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to consumer telehealth growth
- Believe direct-to-consumer distribution will keep winning share in weight loss
- Can tolerate regulatory and legal headline risk
- Prefer a smaller-cap, higher-volatility healthcare name
- Want established, profitable exposure to the GLP-1 market
- Prefer a diversified pharmaceutical company over a single-category platform
- Are comfortable with European pharma valuation and reporting conventions
- Value dividend income alongside growth
| Metric | HIMS | NVO |
|---|---|---|
| AI scorei | 42.5 | 40.8 |
| AI ranki | #1046 | #1088 |
| Latest closei | $29.38 | $39.22 |
| 1M returni | +5.49% | -7.78% |
| 3M returni | -12.77% | -22.84% |
| 6M returni | +8.86% | -2.95% |
| 1Y returni | -53.19% | -27.40% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | HIMS | NVO |
|---|---|---|
| 1Y ago | $4.68K (-53.2%) started 2025-10-15 | $7.62K (-23.8%) started 2025-10-15 |
| 5Y ago | $35.14K (+251.4%) started 2021-10-15 | $9.68K (-3.2%) started 2021-10-15 |
| 10Y ago | $29.98K (+199.8%) started 2019-09-13 | $31.84K (+218.4%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | HIMS | NVO |
|---|---|---|
| Market capi | $6.79B | $173.08B |
| Trailing P/Ei | N/A | 9.59 |
| Forward P/Ei | 29.03 | 1.71 |
| Price/Salesi | N/A | 0.53 |
| EV/Revenuei | 2.85 | 0.82 |
| Analyst targeti | $31.23 | $45.89 |
| Target upsidei | +7.36% | +17.00% |
| Metric | HIMS | NVO |
|---|---|---|
| Revenue growthi | 38.20% | 2.10% |
| Earnings growthi | N/A | -20.60% |
| EPS growthi | N/A | -20.60% |
| FCF margini | +32.95% | +11.44% |
| Operating margini | -12.75% | 42.54% |
| Profit margini | -5.51% | 35.35% |
| ROIC proxyi | -32.03% | 59.81% |
| Return on equityi | -32.03% | 59.81% |
| Dividend yieldi | N/A | 4.58% |
| Payout ratioi | 0.00% | 43.10% |
| Dividend growth streaki | N/A | 7 yrs |
| Betai | 2.42 | 0.38 |
| Debt/equityi | 477.13 | 63.33 |
| Current ratioi | 0.93 | 0.87 |
| Quick ratioi | 0.82 | 0.64 |
Over the past year, HIMS and NVO have moved barely in the same direction (correlation of 0.14), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | HIMS | NVO |
|---|---|---|---|
| 1Y | Growthi | -53.19% | -27.40% |
| CAGRi | -53.21% | -27.42% | |
| Volatilityi | 90.24% | 45.65% | |
| Sharpe ratioi | -0.46 | -0.57 | |
| Sortino ratioi | -0.71 | -0.75 | |
| Max drawdowni | 76.86% | 43.67% | |
| Current drawdowni | 53.19% | 35.64% | |
| Avg drawdowni | 52.10% | 23.92% | |
| Ulcer Indexi | 53.56% | 26.63% | |
| Max daily dropi | 16.03% | 16.43% | |
| Max wkly dropi | 32.71% | 26.95% | |
| 5Y | Growthi | +251.44% | -14.05% |
| CAGRi | +28.58% | -2.98% | |
| Volatilityi | 84.41% | 39.04% | |
| Sharpe ratioi | 0.66 | 0.01 | |
| Sortino ratioi | 1.03 | 0.01 | |
| Max drawdowni | 78.88% | 74.70% | |
| Current drawdowni | 57.26% | 71.09% | |
| Avg drawdowni | 32.82% | 26.51% | |
| Ulcer Indexi | 37.93% | 37.60% | |
| Max daily dropi | 34.63% | 21.83% | |
| Max wkly dropi | 39.06% | 33.45% | |
| 10Y | Growthi | +199.80% | +145.67% |
| CAGRi | +16.75% | +9.41% | |
| Volatilityi | 77.49% | 32.79% | |
| Sharpe ratioi | 0.53 | 0.30 | |
| Sortino ratioi | 0.81 | 0.42 | |
| Max drawdowni | 87.29% | 74.70% | |
| Current drawdowni | 57.26% | 71.09% | |
| Avg drawdowni | 43.81% | 17.30% | |
| Ulcer Indexi | 52.18% | 27.62% | |
| Max daily dropi | 34.63% | 21.83% | |
| Max wkly dropi | 39.06% | 33.45% |
| Category | HIMS | NVO |
|---|---|---|
| Company | Hims & Hers Health, Inc. | Novo Nordisk A/S |
| Sector | Healthcare | Healthcare / Pharmaceuticals |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General |
| Core business | Hims & Hers operates a direct-to-consumer telehealth platform offering subscriptions for weight loss, sexual health, dermatology, and mental health treatments. | Novo Nordisk is a Danish pharmaceutical company and maker of semaglutide-based drugs Ozempic and Wegovy, alongside a broader diabetes and rare-disease portfolio. |
| Investor focus | Investors watch subscriber growth, weight-loss category revenue, and the durability of its restructured distribution partnership with Novo Nordisk for branded GLP-1 drugs. | Investors focus on GLP-1 market share retention against Eli Lilly, manufacturing capacity expansion, and pricing pressure in the U.S. obesity-drug market. |
- Fast-growing subscriber base across a multi-category telehealth platform
- Now an authorized channel for branded Wegovy and Ozempic after settling with Novo Nordisk
- Asset-light model with high gross margins and strong direct-to-consumer marketing reach
- Global leadership in GLP-1 diabetes and obesity treatments
- Large manufacturing capacity expansion underway to meet Wegovy demand
- Diversified pipeline beyond GLP-1, including rare disease and cardiovascular drugs
- Regulatory scrutiny over past compounded-drug marketing and prior legal disputes with Novo Nordisk
- Reliance on continued access to GLP-1 supply on favorable terms
- Rising customer acquisition costs and churn in an increasingly competitive telehealth market
- Intensifying competition from Eli Lilly's tirzepatide franchise
- Pricing pressure and channel disruption from compounded and telehealth-distributed alternatives
- Execution risk on manufacturing scale-up and the oral semaglutide rollout
Compare more than two at a time
This page is a fixed writeup on HIMS and NVO. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside HIMS and NVO, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.